Download the Protocol

Thymosin Alpha-1 (Tα1)

Thymosin Alpha-1 helps strengthen the body’s immune defenses by improving how immune cells communicate and respond. It has been used in medical and research settings to support recovery from illness, improve resilience, and balance immune activity.

Description

• Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino-acid peptide fragment derived from thymosin fraction 5, isolated from the thymus gland.
• Acts as a key immune modulator that enhances defense against infections and supports balanced immune function.
• Approved in multiple countries for treatment of chronic viral infections and immune deficiency syndromes.

How It Works

• Stimulates T-cell activation and improves immune system communication.
• Increases natural killer (NK) cell and cytotoxic T-cell activity.
• Boosts production of interferon-α and other immune-regulating proteins.
• Helps normalize immune responses in both weakened and overactive states.

Documented Effects

• Clinically used in hepatitis B and C, immune suppression, and post-infection recovery.
• Improves vaccine response and supports immune rebuilding after chemotherapy.
• Enhances antiviral defense and modulates inflammation without overstimulation.
• Investigated for cancer immunotherapy, sepsis management, and general immune optimization.

Theoretical Effects

• May help counteract immune aging and chronic inflammation.
• Potential to enhance resistance to infections and improve general recovery speed.
• Synergistic use with Thymalin or Epitalon under investigation for thymic rejuvenation.

Pharmacokinetics

• Half-life: approximately 2 hours following subcutaneous injection.
• Time to peak concentration: about 1–2 hours post-injection.
• Steady-state levels: achieved with repeated dosing over 1–2 weeks.

Duration of Effects

• Immune activation persists 24–48 hours after each dose.
• Immune-regulating benefits can continue for several weeks after a completed course.
• Maintenance dosing may sustain adaptive immunity longer term.

Reconstitution

• Use only bacteriostatic water to reconstitute the lyophilized powder.
• Example vial: 10 mg of Thymosin Alpha-1
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
• Swirl gently to dissolve; avoid shaking or heat exposure.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (Clinical and Research Reference)

Typical Clinical Dose

• Approved clinical regimen: 1.6 mg subcutaneous (SC) twice weekly for 6–12 weeks.
• Alternate clinical protocols: 1.6–3.2 mg SC twice weekly depending on indication.

Common Research Range

• 200–1500 mcg SC 2–3× weekly in immune, viral, or longevity studies.
• Can be paired with thymic peptides for synergistic immune support.

Maximum Weekly Dose

• Clinical use rarely exceeds 6.4 mg per week.
• Higher dosing shows no proportional immune benefit.

Standard Cycle Length

• Typical duration: 6–12 weeks depending on application.
• Maintenance: 1.6 mg SC once weekly or biweekly after main cycle for ongoing support.

Clinical Notes

• Inject subcutaneously in the abdomen or thigh with rotation of sites.
• Can be used in alternating cycles with Thymalin or Epitalon for immune modulation research.
• Do not mix in the same syringe with other peptides.
• Stable for about 30 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes

• Extensively studied; generally well-tolerated with mild side effects (injection redness, fatigue).
• Approved for use under trade names like Zadaxin® in over 30 countries.
• Not approved in all regions; research or medical supervision required.
• Use only high-purity peptide under sterile conditions.